文献速递骨质疏松与代谢性骨病

促卵泡激素与绝经后女性低骨量相关

Follicle-stimulating hormone is associated with low bone mass in postmenopausal women.
PubMed 文献 · Osteoporos Int · 2023-01-24

该横断面研究纳入675名绝经后女性,评估血清促卵泡激素(FSH)与股骨颈及全髋骨密度(BMD)和低骨量/骨质疏松(T值<-1.0)的关联。结果发现FSH最高三分位组较低三分位组股骨颈低骨量/骨质疏松的OR=2.98(95%CI=1.86-4.77),全髋OR=1.74(95%CI=1.06-2.84),且FSH介导了雌二醇与BMD关系的约70%(Sobel检验P<0.001)。

要点

  • FSH最高三分位组股骨颈低骨量/骨质疏松风险约为最低三分位组的2.98倍(OR=2.98,95%CI=1.86-4.77)。
  • FSH最高三分位组全髋低骨量/骨质疏松风险约为最低三分位组的1.74倍(OR=1.74,95%CI=1.06-2.84)。
  • FSH满足介导因子标准,雌二醇与BMD关系的估计衰减约70%(Sobel检验P<0.001)。

核心结论

  • 在健康绝经后女性中,FSH与低骨量/骨质疏松的较高 odds 相关,即使在考虑激素治疗使用后也是如此。
  • FSH是雌二醇与BMD之间关系的介导因子。
  • 需要更大规模的前瞻性研究来探讨FSH浓度与骨骼健康。

研究设计与样本

  • 横断面研究,纳入675名绝经后女性,评估血清FSH与双能X线吸收法(DXA)分类的面积骨密度及股骨颈和全髋低骨量或骨质疏松(T值<-1.0)的关联。
  • 按血清雌二醇中位数分层分析,并使用Sobel检验检测FSH是否介导雌二醇与BMD的关联。

主要发现

  • 线性回归模型中,调整年龄、激素治疗使用和糖尿病后,血清FSH与股骨颈和全髋BMD均呈显著负相关(两者p<0.01)。
  • 完全调整的逻辑回归模型中,FSH最高三分位组较低三分位组股骨颈低骨量/骨质疏松的OR=2.98(95%CI=1.86-4.77)。
  • FSH最高三分位组较低三分位组全髋低骨量/骨质疏松的OR=1.74(95%CI=1.06-2.84)。
  • 分层模型和交互项分析提示雌二醇存在效应修饰。
  • FSH满足介导因子的所有标准,包括雌二醇-BMD关系的估计衰减约70%(Sobel检验P<0.001)。

局限性

  • 需要更大规模的前瞻性研究来探讨FSH浓度与骨骼健康。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We evaluated the influence of two endogenous hormones on bone health in older women. Higher FSH was associated with bone disease, especially in lower estradiol environments. FSH attenuated the relationship between estradiol and bone. This may provide a mechanism through which future clinical research intervenes on bone loss. INTRODUCTION/PURPOSE: Despite preclinical evidence for an inverse association of follicle-stimulating hormone (FSH) and bone mineral density (BMD), no large epidemiologic studies have evaluated the separate and joint influences of FSH and estradiol on bone in postmenopausal women. METHODS: In a cross-sectional study of 675 postmenopausal women, we evaluated associations of serum FSH and dual X-ray absorptiometry (DXA)-classified areal BMD as well as low bone mass or osteoporosis (T-score < - 1.0) of the femoral neck and total hip. We stratified this analysis by serum estradiol (cut at the median). We tested whether FSH mediates the association of estradiol and BMD using the Sobel test. RESULTS: In linear regression models, there was a significant inverse association of serum FSH with both femoral neck and total hip BMD (both p < 0.01) when adjusted for age, hormone therapy (HT) use, and diabetes. In fully adjusted logistic regression models, women in the highest FSH tertile had higher odds of low bone mass/osteoporosis at the femoral neck (OR = 2.98; 95% CI = 1.86-4.77) and at the total hip (OR = 1.74; 95% CI = 1.06-2.84) compared to those in the lowest FSH tertile. We report evidence of effect modification by estradiol in stratified models and an interaction term. FSH met all criteria of a mediator, including an estimated 70% attenuation of the estradiol-BMD relationship (Sobel p value < 0.001). CONCLUSIONS: FSH is associated with higher odds of having low bone mass/osteoporosis even after accounting for HT use. FSH is a mediator of the relationship between estradiol and BMD in healthy postmenopausal women. Larger, prospective studies of FSH concentrations and bone health are needed.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Mattick LJ, Bea JW, Hovey KM, et al. Follicle-stimulating hormone is associated with low bone mass in postmenopausal women. Osteoporos Int. 2023. PMID: 36692543. doi:10.1007/s00198-023-06676-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。